PUBLICATION:
Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30.

AUTHORS:
Retèl V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H.

SUMMARY:
Pooled analysis: he 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen showed the highest survival rates compared to the 70-gene signature, but leads to a substantial larger amount of adjuvant chemotherapy and lower cost-effectiveness.

Read more: Retel et al_2010_Eur J Cancer._The 70-gene Signature